Denali Therapeutics Strategy and Business Model

Executive Overview

Denali Therapeutics is a clinical-stage biotechnology company focused on neurodegenerative diseases and lysosomal storage disorders, with a central emphasis on getting therapeutics into the brain. Founded in 2015 and headquartered in South San Francisco, California, Denali has built its strategy around a set of blood-brain-barrier delivery technologies it calls Transport Vehicles, which are designed to move enzymes, proteins, antibodies, and oligonucleotides into the central nervous system more effectively than conventional approaches. As of 2024, Denali had no approved products; its economic model was still driven by research and development, collaboration revenue, and cash management rather than commercial drug sales. Its most recently reported revenue was #N/A, reflecting collaboration and license activity rather than a marketed-product franchise. Geographically, Denali’s owned operating footprint is centered in the United States, but its clinical and partnership reach is global through alliances with larger biopharma companies and multinational trial networks. The strategic question for Denali is not only whether individual programs succeed, but whether its delivery platform can repeatedly create differentiated central-nervous-system medicines across multiple diseases.

Denali Therapeutics at a Glance

Logo
Common name	Denali Therapeutics
Full legal name	Denali Therapeutics Inc.
Headquarters	South San Francisco, California, United States
Ownership	Public company
Ticker	DNLI
Exchange	NASDAQ
Market Cap	$3.93B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2015; completed Nasdaq IPO in 2017; major collaborations announced with Sanofi in 2018, Biogen in 2020, and Takeda in 2022
Industry or industries	Biotechnology; neuroscience therapeutics; rare disease therapeutics
Key products or services	Clinical-stage therapeutics for neurodegenerative and lysosomal storage diseases; blood-brain-barrier Transport Vehicle platforms; collaboration and licensing activities
Geographic footprint	Primarily U.S.-based operations with global clinical development and partnership reach
Business segments as officially reported	One reportable segment
Company website	https://www.denalitherapeutics.com/

1. What Is the Strategy of Denali Therapeutics?

Using the Playing to Win framework, Denali’s strategy is best understood as a focused attempt to solve one of neuroscience drug development’s hardest problems: reliable delivery into the brain. As of its 2024 public filings and investor materials, Denali’s strategy combines platform science, biomarker-driven development, and selective partnering.

1. 1a. What is the winning aspiration of Denali Therapeutics?

   Denali’s winning aspiration is to develop disease-modifying therapies for neurodegenerative and lysosomal storage diseases by overcoming the blood-brain barrier and translating genetically and biologically validated targets into human benefit. The company has framed success less around a public long-term revenue target and more around clinical and translational proof: demonstrating central nervous system exposure, showing target engagement and biomarker improvement in humans, and ultimately winning regulatory approvals for differentiated therapies. In practical terms, Denali is trying to prove that its Transport Vehicle platform can become a repeatable engine for central nervous system drug development rather than a one-off scientific asset.

2. 1b. Where does Denali Therapeutics play?

   Denali plays in neuroscience and rare disease biopharma, especially diseases where central nervous system access is central to the unmet need. That includes rare lysosomal storage disorders such as Hunter syndrome, genetically defined or mechanistically targeted neurodegenerative diseases such as Parkinson’s disease, and other serious neurologic disorders where target biology is known but delivery has historically been limiting. Denali also plays across multiple therapeutic modalities, including enzymes, proteins, antibodies, oligonucleotides, and selected small molecules. Geographically, its current operating center is the United States, but its development and commercial ambition is global, often pursued with large pharma partners for broader reach.

3. 1c. How does Denali Therapeutics plan to win?

   Denali plans to win through differentiation, not cost leadership. Its core value proposition is that a therapy that reaches the brain more effectively may produce clinical benefits that conventional systemic approaches cannot. The company is also trying to win by being disciplined about target selection and by using biomarkers to de-risk programs earlier. A second element of the recipe is portfolio design: Denali keeps selected programs wholly owned where it may want more strategic or economic control, while partnering other programs with larger companies to share cost, expand modality reach, and reduce portfolio risk. That combination of platform science, translational rigor, and alliance leverage is the essence of Denali’s competitive approach.

4. 1d. What capabilities must Denali Therapeutics have in place?

   To execute this strategy, Denali needs strong protein and molecular engineering capabilities, deep neuroscience and rare disease biology expertise, translational pharmacology, biomarker development, regulatory skill, and the ability to run complex clinical studies in specialist patient populations. It also needs chemistry, manufacturing, and controls expertise for biologics and other advanced modalities, even if manufacturing is outsourced. Because partnerships are a major part of the model, alliance management is another essential capability. Finally, Denali must maintain capital allocation discipline, since development timelines are long and commercial cash flow does not yet fund the business.

5. 1e. What management systems does Denali Therapeutics require?

   Denali requires stage-gated portfolio governance, rigorous safety and quality systems, biomarker-based decision making, and formal alliance-management processes. In a company like Denali, management systems are not just administrative; they determine which programs get advanced, partnered, paused, or stopped. The company also needs cash-runway planning, scenario modeling, and milestone management because collaboration payments, clinical readouts, and regulatory events materially affect strategic flexibility. In effect, Denali’s management system has to connect science, clinical execution, capital discipline, and partnership economics in one coherent operating model.

2. What Are the Current Strategic Initiatives of Denali Therapeutics?

As of Denali’s 2024 public materials, the company’s strategic initiatives were highly program- and platform-specific rather than broad corporate slogans. The main initiatives appear to be the following:

• Advance tividenofusp alfa for Hunter syndrome. Denali has made this program one of its clearest proof points for the Enzyme Transport Vehicle approach. The goal is not just to treat systemic disease, but to address central nervous system manifestations by improving enzyme delivery across the blood-brain barrier. Public updates have emphasized clinical development, biomarker evidence, and regulatory engagement around the path forward.

• Progress the Biogen-partnered BIIB122 program in Parkinson’s disease. BIIB122, formerly DNL151, is a LRRK2 inhibitor intended for Parkinson’s disease. Strategically, the program matters because it gives Denali exposure to a larger neurology market while sharing development cost and commercial risk with an established CNS company.

• Expand and validate the Transport Vehicle platform across multiple cargo types. Denali has publicly positioned its Transport Vehicle technologies as a platform that can be used with enzymes, proteins, antibodies, and oligonucleotides. This is a major strategic initiative because repeated platform validation could increase the company’s odds of producing multiple assets, not just one successful drug.

• Use collaborations to broaden the pipeline while conserving capital. Alliances with companies such as Biogen, Takeda, and Sanofi are part of Denali’s operating strategy, not an adjunct to it. These deals help fund development, provide external validation, and allow Denali to participate in more programs than it could likely finance alone.

• Develop biomarker-rich translational packages. Denali has consistently emphasized biomarkers, pharmacokinetics, pharmacodynamics, and human proof-of-biology. This matters especially in neurology, where clinical endpoints can be slow and noisy. The strategic aim is to make earlier, more evidence-based portfolio decisions.

• Prioritize portfolio discipline. Like many development-stage biotech companies, Denali has to choose where to concentrate capital. Public communications suggest a continued focus on advancing programs with the strongest differentiation, best translational support, and clearest regulatory path while using partnerships to spread risk elsewhere.

3. What Is the Business Model of Denali Therapeutics?

Denali’s current business model is that of a pre-commercial biotechnology company. As of 2024, customers were not buying approved Denali medicines; instead, counterparties were paying for access to Denali’s science through collaboration, licensing, co-development, and milestone-based agreements.

• What customers actually buy: Today, Denali’s economic counterparties primarily buy program rights, shared development arrangements, and access to its Transport Vehicle capabilities. In the future, if therapies are approved, prescribers, health systems, and payers would buy specialty medicines rather than platform access.

• Recurring versus one-time revenue: The current model is a mix of upfront collaboration payments, milestone payments, research support, and revenue recognition over the life of collaboration obligations. That makes revenue somewhat repeat-driven within active alliances but still lumpy and event-driven. It is not a classic recurring subscription model.

• Pricing power: Denali does not yet have observable commercial pricing power because it has no approved products as of 2024. Looking ahead, pricing power would depend on differentiation, clinical evidence, competitive alternatives, and payer scrutiny. In rare diseases, truly differentiated therapies can support premium pricing, but that is still prospective rather than proven in Denali’s case.

• Why the business mix matters: A wholly owned rare-disease asset could yield more retained economics if approved, but it would also require Denali to build more commercialization capability. Partnered larger-market programs can reduce cost and risk, but they also reduce Denali’s share of future upside. That portfolio mix is a major strategic choice.

• What drives gross margin, operating margin, and cash generation: Gross margin is not yet the main lens because product revenue is limited or absent. Operating performance is instead driven by research and development expense, clinical trial spend, platform investment, and milestone timing. Cash generation depends on collaboration inflows, financing flexibility, and disciplined burn management rather than internally generated commercial profits.

• Revenue model: As of 2024, Denali’s revenue model is collaboration-based. If the company commercializes approved therapies, the model would shift toward specialty pharmaceutical sales, likely with a concentrated specialist prescriber base rather than mass-market demand generation.

4. What Products and/or Services Does Denali Therapeutics Sell?

As of 2024, Denali had no approved commercial products. Its most important “offerings” were clinical-stage therapeutic candidates and the underlying delivery technologies that support them.

Core platform offerings

• Enzyme Transport Vehicle (ETV): designed to ferry therapeutic enzymes across the blood-brain barrier for lysosomal and related disorders.

• Protein Transport Vehicle (PTV): intended to deliver larger protein therapeutics into the central nervous system.

• Antibody Transport Vehicle (ATV): designed to enable antibody delivery to the brain.

• Oligonucleotide Transport Vehicle (OTV): intended to improve central nervous system delivery of oligonucleotide-based medicines.

Lead therapeutic programs highlighted publicly as of 2024

• Tividenofusp alfa: a lead ETV-enabled program for Hunter syndrome and one of Denali’s most strategically important wholly owned assets.

• BIIB122: a Biogen-partnered LRRK2 inhibitor for Parkinson’s disease, important both scientifically and economically because it gives Denali participation in a larger-market neurology program.

• DNL343 and other internal or partnered neurology programs: these represent Denali’s effort to maintain exposure beyond a single disease and to build a portfolio rather than a one-asset story.

The most strategically important offerings are not necessarily the ones closest to market alone; they are the programs that can validate Denali’s broader platform. Denali does not have a legacy marketed portfolio to protect, so the key distinction is between earlier small-molecule work and newer Transport Vehicle-enabled biologics and oligonucleotide programs.

5. What Are the Key Competitors or Peers of Denali Therapeutics?

Denali’s competitive set varies by program. Because it is a platform biotech with no broad commercial franchise as of 2024, the best way to think about competition is as a mix of direct disease-specific rivals, neuroscience peers, and platform comparables.

6. What Is the Marketing Strategy of Denali Therapeutics?

As of 2024, Denali’s marketing strategy was primarily science-led and stakeholder-specific, not product-brand-driven. Because the company had no approved products, its most important “marketing” activities were scientific communication, partner positioning, patient-community engagement, and investor credibility.

• Scientific and medical marketing: Denali relies heavily on conference presentations, publications, biomarker data, and clinical updates to build credibility with neurologists, genetic specialists, investigators, and partners.

• Key opinion leader engagement: In specialist diseases, influence runs through expert clinicians and academic centers rather than mass advertising. Denali’s communications strategy appears built around that reality.

• Patient advocacy and disease awareness: In rare diseases especially, education, diagnosis, referral networks, and family advocacy groups matter. For a company like Denali, these activities are as important as traditional brand marketing.

• Business development signaling: A portion of Denali’s external communications also serves a partner-marketing function by demonstrating platform credibility to potential collaborators.

Marketing is therefore a supporting capability rather than the main source of competitive advantage today. The real differentiator is the science. If Denali launches its own rare-disease therapy in the future, its commercial model would likely emphasize targeted field execution, patient services, and market access more than broad-based promotion.

7. What Are the Key Customer Segments of Denali Therapeutics?

Denali’s customer picture depends on whether one looks at the company today or at its likely future commercial state.

• Current economic customers: pharmaceutical partners. As of 2024, the clearest revenue-generating counterparties were collaboration partners such as Biogen, Takeda, and Sanofi. That means Denali’s current revenue base is concentrated rather than broadly diversified.

• Clinical ecosystem customers and influencers: investigators, academic medical centers, rare-disease specialists, movement-disorder neurologists, and trial networks are essential to development even if they are not “customers” in the accounting sense.

• Future prescriber segments: if Denali commercializes therapies itself, the most important prescribers would likely be pediatric neurologists, metabolic-genetics specialists, movement-disorder specialists, and other subspecialists concentrated in a relatively small number of expert centers.

• Payers and health systems: for rare or high-cost neurologic therapies, commercial insurers, government payers, and hospital systems become critical economic customers because reimbursement often determines practical uptake.

• Patients and families: in rare disease, patient communities are strategically important because diagnosis, referral, adherence, and support services are central to treatment access.

So Denali is diversified by scientific opportunity, but as of 2024 it is still relatively concentrated by current revenue source.

8. What Is the Sales Model of Denali Therapeutics?

Denali did not have a traditional product-sales model as of 2024. Its present go-to-market model is best described as science-led partnering plus clinical development execution.

Current model

Today, Denali creates value by discovering and advancing programs, then retaining, sharing, or monetizing rights through collaboration agreements. Sales effort, in effect, is business development: negotiating licenses, structuring co-development arrangements, and demonstrating platform value to partners and investors.

Likely future commercial model

If Denali commercializes approved therapies directly, the most likely model is a concentrated specialty-sales approach. That would involve a relatively small field force, strong medical affairs coverage, focused account management at major treatment centers, patient-support services, and reimbursement infrastructure rather than a large primary-care sales organization. That inference fits the company’s rare-disease and specialist-neurology focus.

Why channel structure matters

A concentrated specialist channel can be attractive because it allows high customer intimacy and tighter launch execution with a leaner footprint. But it also raises the stakes on market access, patient identification, and operational precision. For a company like Denali, that creates significant value in launch readiness, referral pathway design, field deployment, and payer strategy.

9. In What Geographies Does Denali Therapeutics Operate?

Denali’s owned operating footprint is primarily in the United States, centered on its headquarters and research presence in South San Francisco, California. Unlike a mature global pharmaceutical company, Denali does not present itself as having a large, owned commercial or manufacturing network across many countries.

• Core operating base: South San Francisco is the center of the company’s research, management, and development infrastructure.

• Clinical footprint: Denali’s clinical trials and specialist-site relationships give it a broader geographic footprint than its owned facilities alone would suggest. Rare disease and neurology studies often require multinational enrollment.

• Partnership footprint: Collaborations with Biogen, Takeda, and Sanofi extend Denali’s effective reach into Europe, Japan, and other international markets through partners with global development and commercialization capability.

• Operations model: Denali appears more networked than physically dispersed, relying on contract manufacturers, contract research organizations, laboratories, and alliance partners rather than on a broad owned plant footprint.

In short, Denali is geographically concentrated in its owned infrastructure but globally exposed through trials, science, and partnerships.

10. Who Are the Owners of Denali Therapeutics?

Denali is a publicly traded company listed on Nasdaq under the ticker DNLI. As of its 2024 public ownership disclosures, the company did not disclose a single controlling shareholder. Its shareholder base has historically included venture-origin holders such as ARCH Venture-related entities, along with large institutional investors and healthcare-focused funds. Because beneficial ownership can change materially over time, the latest proxy statement and SEC Schedule 13G and 13D filings are the best sources for current large-shareholder positions.

11. How Is Denali Therapeutics Organized?

As of 2024, Denali reported one reportable segment, which is typical for a development-stage biotech whose economics are not yet organized around multiple commercial divisions. Practically, the company appears organized around a combination of functional expertise and program teams.

• Research and platform development: discovery biology, translational science, biomarker work, and Transport Vehicle engineering.

• Clinical development: program leadership, clinical operations, regulatory affairs, medical, and safety functions supporting trials.

• Technical operations: chemistry, manufacturing, and controls, process development, and external manufacturing oversight.

• Corporate and alliance management: finance, legal, business development, and collaboration governance for partnered programs.

This is less a divisional portfolio company than an integrated R&D platform company with multiple disease programs running through a shared scientific infrastructure.

12. How Does Denali Therapeutics Operate?

Denali operates as a platform-driven drug developer. Day to day, the company’s value creation comes from turning neuroscience insight and delivery technology into investable drug candidates, then advancing them through preclinical and clinical development.

1. Target and program selection: Denali starts with disease biology, often emphasizing genetically or mechanistically validated targets in neurodegeneration and rare neurologic disease.

2. Molecule engineering: the company designs therapeutic constructs, including Transport Vehicle-enabled biologics and other modalities intended to improve central nervous system delivery.

3. Preclinical and translational work: Denali generates pharmacology, distribution, and biomarker data to test whether a candidate is reaching the right tissues and affecting the intended biology.

4. Clinical execution: it runs trials through specialist investigators and contract research partners, often in narrow patient populations where recruitment and endpoint design are difficult.

5. Manufacturing oversight: Denali does not operate like a fully integrated large-cap pharma manufacturer; it relies heavily on external production partners while retaining technical and quality oversight.

6. Partner management: for collaborated programs, Denali has to coordinate governance, data sharing, development plans, and economics with counterparties.

The main operational bottlenecks are the usual ones for CNS biotech, but amplified: proving target engagement in the brain, recruiting the right patients, managing complex manufacturing for biologics, and making disciplined decisions under uncertainty.

13. What Are the Growth Opportunities for Denali Therapeutics?

Management-stated priorities and the public pipeline suggest several plausible growth opportunities for Denali.

• Converting lead rare-disease programs into approved products. The clearest near- to medium-term opportunity is successful development and possible commercialization of tividenofusp alfa and other Transport Vehicle-enabled rare-disease assets. A successful launch would fundamentally change Denali’s business model.

• Platform expansion across multiple modalities. If Denali can repeatedly show that its Transport Vehicle technologies work for enzymes, proteins, antibodies, and oligonucleotides, its addressable opportunity expands well beyond one indication.

• More value from partnered larger-market neurology programs. Programs such as BIIB122 offer potential upside in diseases with much larger patient populations than rare lysosomal disorders, albeit with shared economics.

• Additional business development. Denali’s platform is also a source of potential growth through new licensing or co-development deals, particularly where partners bring commercialization scale or complementary modality expertise.

• Geographic expansion through partners. For a company with limited owned commercial infrastructure, international growth is most plausibly captured through alliance structures rather than immediate stand-alone buildout.

• Portfolio compounding. The most attractive upside case is that one validated Transport Vehicle platform lowers the development hurdle for later programs, improving capital efficiency over time.

The main constraints are clinical risk, regulatory uncertainty, manufacturing complexity, narrow patient pools in rare disease, and the capital intensity of running multiple programs before commercial cash flows arrive.

14. What Is the History of Denali Therapeutics?

• 2015: Denali was founded in South San Francisco by Ryan Watts, Marc Tessier-Lavigne, and Alexander Schuth to focus on neurodegenerative disease drug development.

• 2017: The company completed its initial public offering on Nasdaq, giving it the capital to build out its neuroscience pipeline and platform capabilities.

• 2018: Denali announced a major collaboration with Sanofi, an early sign that larger pharmaceutical companies saw value in its neuroscience and platform approach.

• 2020: Denali entered a significant collaboration with Biogen around the LRRK2 program and additional Transport Vehicle-related work, deepening its position in Parkinson’s disease and CNS partnering.

• 2022: Denali announced a collaboration with Takeda, further validating its Protein Transport Vehicle strategy and broadening the partnered pipeline.

• 2023-2024: The company continued to advance lead clinical programs, especially tividenofusp alfa and BIIB122, while positioning the Transport Vehicle platform as the central strategic asset.

Denali’s history is notable less for acquisitions or corporate restructurings than for building a platform-centric neuroscience biotech with repeated external validation through partnerships.

15. What Are the Key Assets of Denali Therapeutics?

Denali is not asset-heavy in the way an airline or industrial manufacturer is, but several assets are strategically central.

• Transport Vehicle intellectual property and know-how: this is Denali’s most distinctive strategic asset and the foundation of much of its partnering value.

• Clinical pipeline and human data packages: lead programs such as tividenofusp alfa and BIIB122 matter not just for their own value, but because they can validate the platform.

• Biomarker and translational datasets: in central nervous system drug development, these are high-value assets because they influence go/no-go decisions and partner confidence.

• Collaboration agreements: Denali’s alliances with large pharma companies are economic assets in their own right because they provide funding, milestones, and strategic reach.

• Liquidity: as of 2024, Denali reported a substantial cash and investment position relative to many development-stage peers, which is itself a competitive asset because it extends strategic runway.

• Specialized scientific team and research infrastructure: in biotech, talent and laboratory capability are often more valuable than owned hard assets.

16. What Is the Technology Strategy of Denali Therapeutics?

Technology is central to Denali’s strategy. The company is not simply pursuing neuroscience targets; it is trying to build a differentiated technology layer that changes how drugs are delivered into the brain.

The core of that strategy is the Transport Vehicle platform, which is designed to use receptor-mediated transport mechanisms to move therapeutic cargo across the blood-brain barrier. Denali has extended that concept across multiple modalities, including enzymes, proteins, antibodies, and oligonucleotides. That matters because it gives the company a chance to reuse a core delivery architecture rather than inventing a new delivery solution for every program.

Technology serves two roles at Denali. First, it is an internal enabler that supports molecule design, tissue distribution, biomarker work, and translational decision making. Second, it is part of the customer offering when Denali collaborates with other biopharma companies, since partners are effectively buying access to a differentiated delivery capability. That makes technology strategy inseparable from business strategy at Denali.

17. What Is the R&D Strategy of Denali Therapeutics?

R&D is the center of the Denali story. As of 2024, the company’s R&D strategy appears to have four defining features.

• Focus on biologically grounded targets. Denali has consistently emphasized mechanistic and often genetically informed neuroscience, which is intended to improve the odds that target modulation matters clinically.

• Use biomarkers early and heavily. In central nervous system development, waiting for long-duration clinical outcomes can be expensive and ambiguous. Denali’s approach tries to generate earlier evidence through target engagement and pharmacodynamic markers.

• Build reusable platform science. Rather than treating each program as a standalone asset, Denali invests in platform technologies that can feed multiple programs and collaborations.

• Balance owned and partnered development. Denali’s R&D portfolio is structured so that some programs can potentially create high retained value if successful, while partnered assets allow risk sharing and broader reach.

That strategy is attractive if the platform keeps working, but it also creates a high standard of proof. Investors and partners are not only asking whether one molecule succeeds; they are asking whether Denali’s research engine can systematically produce central nervous system medicines with better delivery and better biology.

18. What Is the Finance Strategy of Denali Therapeutics?

Denali’s finance strategy, as of 2024, is typical of a well-capitalized development-stage biotech but with an added emphasis on partnership economics. The company has generally funded itself through a combination of public-market capital and significant collaboration cash flows rather than through heavy financial leverage.

• Maintain a strong liquidity buffer: cash runway is strategic in biotech because it determines how many clinical inflection points a company can reach without raising capital under pressure.

• Allocate capital primarily to R&D: Denali’s spending is directed mainly toward pipeline advancement, platform expansion, and technical operations rather than toward a large commercial infrastructure.

• Use partnerships as a financing tool: collaborations do more than validate the science; they can bring upfront payments, milestones, and cost sharing that reduce net cash burn.

• Stay selective on commercialization buildout: until a product is close to market, keeping selling, general, and administrative expense relatively lean supports strategic flexibility.

• No dividend or buyback orientation: like most clinical-stage biotech companies, Denali’s capital allocation priority is reinvestment, not shareholder distributions.

In practical terms, finance strategy at Denali is about buying enough time and flexibility for the science to mature while avoiding unnecessary dilution and preserving optionality around which assets to own versus partner.

19. How Companies Like Denali Therapeutics Leverage Independent Consultants through Umbrex

Companies like Denali turn to Umbrex when they need senior consulting talent with top-tier training but do not need a full large-firm team and its overhead. Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other leading firms. For a company like Denali, that matters because strategic needs often arise in narrow, high-stakes bursts: portfolio decisions, launch planning, alliance management, operations design, market access, finance, technology, and AI. Umbrex can provide specialists across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI.

• R&D portfolio prioritization: build a decision framework across wholly owned and partnered programs, balancing probability of technical success, capital needs, strategic fit, and value inflection timing.

• Rare-disease launch readiness: prepare commercialization plans for a potential Hunter syndrome launch, including treatment-center mapping, patient journey design, and field-force sizing.

• Patient-finding and referral strategy: identify where eligible rare-disease patients are likely to be diagnosed, missed, or referred late, and design outreach and support models around specialist centers.

• Alliance governance improvement: redesign how Denali manages complex collaborations with partners such as Biogen, Takeda, and Sanofi, including decision rights, escalation processes, and joint steering effectiveness.

• Market access and evidence strategy: develop payer value stories, evidence-generation plans, and reimbursement scenarios for high-cost central nervous system or rare-disease therapies.

• CMC and external manufacturing strategy: assess contract development and manufacturing organization networks, tech-transfer plans, and operating models for biologics and other advanced modalities.

• Clinical operations optimization: improve site selection, recruitment planning, vendor management, and trial execution for rare-disease and specialist-neurology studies.

• Business development screening: identify external assets, targets, or platform partners that could complement Denali’s Transport Vehicle capabilities.

• Organization design for scale-up: help Denali evolve from a platform-focused R&D biotech into a company that can selectively commercialize while still preserving scientific agility.

• Capital allocation and runway planning: model alternative spending, partnering, and financing scenarios tied to major clinical and regulatory milestones.